Cnbx Pharmaceuticals INC
Market Movers (8-K)
OID
CNBX Pharmaceuticals Inc. has secured a $45,000 non-convertible promissory note from 3i L.P. to fund immediate working capital needs, incurring a 20% premium on all repayments.
Capital raise
Worse than expected
OID
CNBX Pharmaceuticals entered into a convertible promissory note agreement for an immediate $55,000 and potential additional funding up to $850,000.
Capital raise
OID
CNBX Pharmaceuticals has replaced its independent auditor, Weinstein International CPA, with Elkana Amitai, CPA, effective March 18, 2024.
Quarterly Earnings (10-Q)
OID
CNBX Pharmaceuticals reports a net loss of $154,165 for the third quarter of 2026 as it continues to develop its oncology drug candidate, RCC-33.
Capital raise
OID
CNBX Pharmaceuticals Inc. reported a wider net loss for the six months ended February 28, 2026, with cash reserves decreasing, raising going concern doubts.
Worse than expected
Capital raise
OID
CNBX Pharmaceuticals Inc. reported a significant increase in net loss and a critically low cash position for the three months ended November 30, 2025, raising substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
OID
10-Q: CNBX Pharmaceuticals Faces Severe Financial Headwinds with Zero Revenue and Going Concern Warning
CNBX Pharmaceuticals Inc. reported no revenue and a critically low cash position in its latest 10-Q filing, raising substantial doubt about its ability to continue as a going concern amidst a significant reduction in operational activities.
Capital raise
Worse than expected
OID
CNBX Pharmaceuticals' Q2 2025 report reveals decreased operating expenses due to funding constraints, alongside ongoing efforts to advance its colorectal cancer drug candidate.
Capital raise
Worse than expected
OID
CNBX Pharmaceuticals reported a net loss of $34,352 for the quarter ended November 30, 2024, with reduced operating expenses and ongoing concerns about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
CNBX Pharmaceuticals Inc. reported no revenue for the fiscal year ended August 31, 2025, with a net loss of $313,976, and auditors expressing substantial doubt about its ability to continue as a going concern.
Delay expected
Capital raise
Worse than expected
OID
CNBX Pharmaceuticals Inc., a clinical-stage company, released its annual report, highlighting its focus on developing cannabinoid-based cancer treatments and its plans for upcoming clinical trials.
Capital raise
Worse than expected
Schedule 13G - Passive Investments
OID
3i, LP and associated entities report a 9.9% beneficial ownership stake in CNBX Pharmaceuticals following recent share issuances.
Capital raise
OID
SCHEDULE: 3i LP Updates CNBX Pharma Stake to 9.99%
3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has updated its beneficial ownership in CNBX Pharmaceuticals Inc. to 9.99% through a convertible note.
Capital raise
OID
3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has updated its beneficial ownership in CNBX Pharmaceuticals Inc. to 9.99%, comprising direct shares and convertible note holdings.
Capital raise
OID
SCHEDULE: 3i LP Boosts CNBX Pharma Stake to 9.9%
3i, LP and its affiliates have updated their beneficial ownership in CNBX Pharmaceuticals Inc. to 9.9% of outstanding common stock, totaling 13,573,116 shares.
OID
SCHEDULE 13G/A: 3i LP and Affiliates Maintain 9.9% Stake in CNBX Pharmaceuticals, Update Beneficial Ownership Filing
3i, LP, 3i Management LLC, and Maier Joshua Tarlow have filed an Amendment No. 4 to their Schedule 13G, reporting a combined beneficial ownership of 9.9% of CNBX Pharmaceuticals Inc.'s common stock as of March 31, 2025.
OID
SCHEDULE 13G/A: 3i LP Updates Significant Stake in CNBX Pharmaceuticals, Maintaining 9.9% Beneficial Ownership
3i, LP, along with its affiliates, has filed an Amendment No. 3 to its Schedule 13G, reaffirming its beneficial ownership of 9.9% of CNBX Pharmaceuticals Inc.'s common stock as of December 31, 2024.
Capital raise